<p>D. E. Shaw &amp; Co. Inc. 在最近向美国证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Sight Sciences, Inc. (NASDAQ:SGHT - 免费报告) 的股份增加了 27.6%。该公司在季度内购买了额外的 88,738 股后，持有 410,325 股该公司的股票。D. E. Shaw &amp; Co. Inc. 在最近一个季度末拥有约 0.81% 的 Sight Sciences，价值 1,494,000 美元。</p>
<p>获取 <strong>Sight Sciences</strong> 警报：</p>
<p>其他几家机构投资者和对冲基金最近也买卖了 SGHT 的股票。Long Focus Capital Management LLC 在第四季度将其在 Sight Sciences 的股份增加了 158.8%。Long Focus Capital Management LLC 目前拥有 2,238,632 股该公司的股票，价值 8,149,000 美元，此前在该期间内又收购了 1,373,535 股。Geode Capital Management LLC 在第四季度将其在 Sight Sciences 的股份增加了 1.1%。Geode Capital Management LLC 目前拥有 792,860 股该公司的股票，价值 2,887,000 美元，此前在上个季度又收购了 8,731 股。B Group Inc. 在第四季度购买了价值约 2,291,000 美元的 Sight Sciences 新头寸。Renaissance Technologies LLC 在第四季度将其在 Sight Sciences 的股份增加了 654.3%。Renaissance Technologies LLC 目前拥有 393,006 股该公司的股票，价值 1,431,000 美元，此前在上个季度又购买了 340,906 股。最后，Northern Trust Corp 在第四季度将其在 Sight Sciences 的持股增加了 2.1%。Northern Trust Corp 目前拥有 332,491 股该公司的股票，价值 1,210,000 美元，此前在上个季度又收购了 6,727 股。当前 55.51% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>内部活动</h2>
<p>在其他消息中，执行副总裁 Manohar K. Raheja 于 3 月 12 日星期三购买了 10,000 股 Sight Sciences 股票，交易的平均成本为每股 2.73 美元，总交易额为 27,300.00 美元。收购完成后，该执行副总裁现在拥有 145,000 股该公司的股票，价值 395,850 美元。这笔交易代表了其持股的 7.41% 增加。该购买在向美国证券交易委员会的文件中披露，可以通过美国证券交易委员会网站访问。此外，首席执行官 Paul Badawi 于 4 月 1 日星期二出售了 24,174 股该公司的股票，平均售价为每股 2.30 美元，总交易额为 55,600.20 美元。出售完成后，首席执行官现在拥有 6,010,580 股该公司的股票，价值 13,824,334 美元。这代表了其持股的 0.40% 减少。该出售的披露信息可以在此找到。在过去三个月中，内部人士已出售 35,196 股公司股票，价值 81,001 美元。当前 30.90% 的股票由公司内部人士持有。</p>
<h2>Sight Sciences 价格表现</h2>
<p>SGHT 股票在星期五开盘价为 3.28 美元。Sight Sciences, Inc. 的 12 个月低点为 2.03 美元，12 个月高点为 8.45 美元。该公司的流动比率为 10.18，速动比率为 9.74，债务与股本比率为 0.36。该股票的 50 日简单移动平均为 2.82 美元，200 日简单移动平均为 3.13 美元。该股票的市值为 1.6956 亿美元，市盈率为 -3.22，贝塔值为 2.41。</p>
<p>Sight Sciences (NASDAQ:SGHT - 获取免费报告) 最近于 5 月 8 日星期四发布了其财报。该公司报告本季度每股收益 (EPS) 为 -0.28 美元，超出市场共识预期的 -0.29 美元 0.01 美元。Sight Sciences 的净利润率为 -63.30%，股本回报率为 -47.28%。该公司本季度的收入为 1,751 万美元，而分析师预期为 1,651 万美元。分析师平均预测 Sight Sciences, Inc. 本财年将发布 -0.99 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<p>一些研究公司最近对 SGHT 进行了评估。Lake Street Capital 将 Sight Sciences 的目标价格从 2.50 美元上调至 3.00 美元，并在 5 月 9 日星期五的报告中给予该股票 &#34;持有&#34; 评级。Piper Sandler 将 Sight Sciences 的目标价格从 5.50 美元下调至 3.50 美元，并在 3 月 6 日星期四的报告中为该公司设定了 &#34;中性&#34; 评级。Stifel Nicolaus 将 Sight Sciences 的目标价格从 5.00 美元下调至 4.00 美元，并在 3 月 6 日星期四的研究报告中为该公司设定了 &#34;买入&#34; 评级。花旗集团将 Sight Sciences 的目标价格从 3.20 美元上调至 3.60 美元，并在周四的研究报告中给予该股票 &#34;中性&#34; 评级。最后，瑞银集团将 Sight Sciences 的目标价格从 5.50 美元下调至 5.00 美元，并在 1 月 27 日星期一的研究报告中为该公司设定了 &#34;买入&#34; 评级。五位分析师对该股票给予了持有评级，两位分析师给予了买入评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;持有&#34;，平均目标价格为 4.02 美元。</p>
<p><strong>查看我们最新的 SGHT 股票分析</strong></p>
<h2>关于 Sight Sciences</h2>
<p>(免费报告)</p>
<p>Sight Sciences, Inc. 是一家眼科医疗设备公司，专注于开发和商业化用于治疗眼病的外科和非外科技术。它通过两个部门运营，分别是外科青光眼和干眼。该公司的产品包括 OMNI 外科系统，这是一种无植入物的青光眼手术技术，旨在降低患有原发性开角型青光眼的成年患者的眼内压；以及 SION 外科仪器，这是一种手动操作的设备，用于眼科手术中切除小梁网。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们认为比 Sight Sciences 更好的股票</li>
<li>CD 计算器：定期存款计算器</li>
<li>Joby 股票的动荡：近期下跌背后的原因是什么？</li>
<li>成长投资：你应该在 2022 年采用这种投资策略吗？</li>
<li>为什么嘉年华可能是终极非科技成长股</li>
<li>复利是如何计算的？</li>
<li>超微计算机股票因沙特订单而开辟新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
<p>在你考虑 Sight Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Sight Sciences 并不在名单上。</p>
<p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SGHT

<p>D. E. Shaw & Co. Inc. 在第四季度增加了对 Sight Sciences, Inc. (NASDAQ:SGHT) 的持股比例，增幅为 27.6%，额外购买了 88,738 股，使其总持股达到 410,325 股，价值 149 万美元。其他机构投资者也增加了他们的持股。该股票开盘价为 3.28 美元，12 个月的价格区间为 2.03 美元至 8.45 美元。Sight Sciences 报告的季度每股收益为（0.28 美元），超出预期，收入为 1751 万美元。分析师预测当前财年的每股收益为-0.99，目标价格从 2.50 美元到 5.00 美元不等</p>

<p>D. E. Shaw &amp; Co. Inc. increased its stake in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 27.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 410,325 shares of the company's stock after purchasing an additional 88,738 shares during the quarter. D. E. Shaw &amp; Co. Inc. owned approximately 0.81% of Sight Sciences worth $1,494,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>D. E. Shaw &amp; Co. Inc. 在最近向美国证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Sight Sciences, Inc. (NASDAQ:SGHT - 免费报告) 的股份增加了 27.6%。该公司在季度内购买了额外的 88,738 股后，持有 410,325 股该公司的股票。D. E. Shaw &amp; Co. Inc. 在最近一个季度末拥有约 0.81% 的 Sight Sciences，价值 1,494,000 美元。</p>
</div><p>Get <strong>Sight Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sight Sciences</strong> 警报：</p>
</div><p>Several other institutional investors and hedge funds also recently bought and sold shares of SGHT. Long Focus Capital Management LLC raised its stake in Sight Sciences by 158.8% during the 4th quarter. Long Focus Capital Management LLC now owns 2,238,632 shares of the company's stock worth $8,149,000 after acquiring an additional 1,373,535 shares during the period. Geode Capital Management LLC grew its stake in Sight Sciences by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 792,860 shares of the company's stock valued at $2,887,000 after acquiring an additional 8,731 shares in the last quarter. B Group Inc. bought a new position in shares of Sight Sciences during the 4th quarter valued at about $2,291,000. Renaissance Technologies LLC boosted its stake in Sight Sciences by 654.3% during the fourth quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock valued at $1,431,000 after buying an additional 340,906 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Sight Sciences by 2.1% during the 4th quarter. Northern Trust Corp now owns 332,491 shares of the company's stock worth $1,210,000 after acquiring an additional 6,727 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也买卖了 SGHT 的股票。Long Focus Capital Management LLC 在第四季度将其在 Sight Sciences 的股份增加了 158.8%。Long Focus Capital Management LLC 目前拥有 2,238,632 股该公司的股票，价值 8,149,000 美元，此前在该期间内又收购了 1,373,535 股。Geode Capital Management LLC 在第四季度将其在 Sight Sciences 的股份增加了 1.1%。Geode Capital Management LLC 目前拥有 792,860 股该公司的股票，价值 2,887,000 美元，此前在上个季度又收购了 8,731 股。B Group Inc. 在第四季度购买了价值约 2,291,000 美元的 Sight Sciences 新头寸。Renaissance Technologies LLC 在第四季度将其在 Sight Sciences 的股份增加了 654.3%。Renaissance Technologies LLC 目前拥有 393,006 股该公司的股票，价值 1,431,000 美元，此前在上个季度又购买了 340,906 股。最后，Northern Trust Corp 在第四季度将其在 Sight Sciences 的持股增加了 2.1%。Northern Trust Corp 目前拥有 332,491 股该公司的股票，价值 1,210,000 美元，此前在上个季度又收购了 6,727 股。当前 55.51% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Manohar K. Raheja bought 10,000 shares of Sight Sciences stock in a transaction on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the acquisition, the executive vice president now owns 145,000 shares of the company's stock, valued at $395,850. This trade represents a 7.41% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Paul Badawi sold 24,174 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the sale, the chief executive officer now owns 6,010,580 shares in the company, valued at $13,824,334. This represents a 0.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,196 shares of company stock worth $81,001. 30.90% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Manohar K. Raheja 于 3 月 12 日星期三购买了 10,000 股 Sight Sciences 股票，交易的平均成本为每股 2.73 美元，总交易额为 27,300.00 美元。收购完成后，该执行副总裁现在拥有 145,000 股该公司的股票，价值 395,850 美元。这笔交易代表了其持股的 7.41% 增加。该购买在向美国证券交易委员会的文件中披露，可以通过美国证券交易委员会网站访问。此外，首席执行官 Paul Badawi 于 4 月 1 日星期二出售了 24,174 股该公司的股票，平均售价为每股 2.30 美元，总交易额为 55,600.20 美元。出售完成后，首席执行官现在拥有 6,010,580 股该公司的股票，价值 13,824,334 美元。这代表了其持股的 0.40% 减少。该出售的披露信息可以在此找到。在过去三个月中，内部人士已出售 35,196 股公司股票，价值 81,001 美元。当前 30.90% 的股票由公司内部人士持有。</p>
</div><h2>Sight Sciences Price Performance</h2>
<div class="lb-trans"><h2>Sight Sciences 价格表现</h2>
</div><p>Shares of SGHT stock opened at $3.28 on Friday. Sight Sciences, Inc. has a twelve month low of $2.03 and a twelve month high of $8.45. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $2.82 and a two-hundred day simple moving average of $3.13. The stock has a market capitalization of $169.56 million, a price-to-earnings ratio of -3.22 and a beta of 2.41.</p>
<div class="lb-trans"><p>SGHT 股票在星期五开盘价为 3.28 美元。Sight Sciences, Inc. 的 12 个月低点为 2.03 美元，12 个月高点为 8.45 美元。该公司的流动比率为 10.18，速动比率为 9.74，债务与股本比率为 0.36。该股票的 50 日简单移动平均为 2.82 美元，200 日简单移动平均为 3.13 美元。该股票的市值为 1.6956 亿美元，市盈率为 -3.22，贝塔值为 2.41。</p>
</div><p>Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $17.51 million for the quarter, compared to analysts' expectations of $16.51 million. On average, analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Sight Sciences (NASDAQ:SGHT - 获取免费报告) 最近于 5 月 8 日星期四发布了其财报。该公司报告本季度每股收益 (EPS) 为 -0.28 美元，超出市场共识预期的 -0.29 美元 0.01 美元。Sight Sciences 的净利润率为 -63.30%，股本回报率为 -47.28%。该公司本季度的收入为 1,751 万美元，而分析师预期为 1,651 万美元。分析师平均预测 Sight Sciences, Inc. 本财年将发布 -0.99 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research firms have recently weighed in on SGHT. Lake Street Capital boosted their target price on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a &#34;hold&#34; rating in a report on Friday, May 9th. Piper Sandler lowered their target price on shares of Sight Sciences from $5.50 to $3.50 and set a &#34;neutral&#34; rating for the company in a report on Thursday, March 6th. Stifel Nicolaus decreased their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, March 6th. Citigroup raised their price target on Sight Sciences from $3.20 to $3.60 and gave the stock a &#34;neutral&#34; rating in a research note on Thursday. Finally, UBS Group decreased their target price on Sight Sciences from $5.50 to $5.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, January 27th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and an average price target of $4.02.</p>
<div class="lb-trans"><p>一些研究公司最近对 SGHT 进行了评估。Lake Street Capital 将 Sight Sciences 的目标价格从 2.50 美元上调至 3.00 美元，并在 5 月 9 日星期五的报告中给予该股票 &#34;持有&#34; 评级。Piper Sandler 将 Sight Sciences 的目标价格从 5.50 美元下调至 3.50 美元，并在 3 月 6 日星期四的报告中为该公司设定了 &#34;中性&#34; 评级。Stifel Nicolaus 将 Sight Sciences 的目标价格从 5.00 美元下调至 4.00 美元，并在 3 月 6 日星期四的研究报告中为该公司设定了 &#34;买入&#34; 评级。花旗集团将 Sight Sciences 的目标价格从 3.20 美元上调至 3.60 美元，并在周四的研究报告中给予该股票 &#34;中性&#34; 评级。最后，瑞银集团将 Sight Sciences 的目标价格从 5.50 美元下调至 5.00 美元，并在 1 月 27 日星期一的研究报告中为该公司设定了 &#34;买入&#34; 评级。五位分析师对该股票给予了持有评级，两位分析师给予了买入评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;持有&#34;，平均目标价格为 4.02 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on SGHT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 SGHT 股票分析</strong></p>
</div><h2>About Sight Sciences</h2>
<div class="lb-trans"><h2>关于 Sight Sciences</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.</p>
<div class="lb-trans"><p>Sight Sciences, Inc. 是一家眼科医疗设备公司，专注于开发和商业化用于治疗眼病的外科和非外科技术。它通过两个部门运营，分别是外科青光眼和干眼。该公司的产品包括 OMNI 外科系统，这是一种无植入物的青光眼手术技术，旨在降低患有原发性开角型青光眼的成年患者的眼内压；以及 SION 外科仪器，这是一种手动操作的设备，用于眼科手术中切除小梁网。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Sight Sciences</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>How is Compound Interest Calculated?</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Sight Sciences 更好的股票</li>
<li>CD 计算器：定期存款计算器</li>
<li>Joby 股票的动荡：近期下跌背后的原因是什么？</li>
<li>成长投资：你应该在 2022 年采用这种投资策略吗？</li>
<li>为什么嘉年华可能是终极非科技成长股</li>
<li>复利是如何计算的？</li>
<li>超微计算机股票因沙特订单而开辟新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SGHT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
</div><p>Before you consider Sight Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Sight Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Sight Sciences 并不在名单上。</p>
</div><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

D. E. Shaw & Co. Inc. 收购了 Sight Sciences, Inc.（NASDAQ:SGHT）的 88,738 股股票